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Abstract: Amrubicin is a synthetic 9-aminoanthracycline that has
significant antitumor activity in Japanese patients with extensive
stage small cell lung cancer (SCLC). Clinical trials ongoing in the
Untied States and Europe will determine whether amrubicin will be
effective in other ethnic groups (whites) or whether this will be an
example of geographic and/or genetic variation. Genetic polymor-
phisms in the UGT1A1 gene have been identified as one of the
causes of the increased diarrhea seen in white patients treated with
irinotecan when compared with Japanese patients. Nicotinamide
adenine dinucleotide phosphate, reduced form–quinone oxidoreductase
(NQ01) is an enzyme that participates in the metabolism of amrubicin
and polymorphisms of the enzyme, known to occur in the Asian
population, might explain the effectiveness of the drug in Japanese
patients with small cell lung cancer. Studies to evaluate the drug in US
and European patients with extensive stage small cell lung cancer are
ongoing. Levels of NQ01 will also be determined in these studies.
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Small cell lung cancer (SCLC) accounts for approximately13% of new cases of lung cancer diagnosed in the United
States.1 Sixty percent to 70% of patients with SCLC present
with extensive-stage SCLC (i.e., metastatic disease), whereas
30% to 40% of patients have limited-stage SCLC, defined as
disease confined to one hemithorax with or without regional
lymph nodes (hilar or mediastinal), with or without ipsilateral
supraclavicular lymph node involvement, and without ipsi-
lateral pleural effusions.2
SCLC is a rapidly proliferating tumor that responds
both to chemotherapy and radiation therapy. Unfortunately,
although limited-stage SCLC is potentially curable with com-
bined modality therapy (i.e., 15%–25% 5-year survival rate),
extensive stage, despite treatment with chemotherapy, has a
poor long-term survival rate, with almost all such patients
dead within 2 years from initial diagnosis.3
Despite the introduction of effective chemotherapeutic
drugs in the treatment of untreated SCLC patients in the 1990s
(i.e., paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine,
gemcitabine), there has been no significant improvement in the
survival of patients with SCLC (Table 1).4–11
There is a need for new and effective agents to treat
patients with SCLC. One such new agent may be amrubicin,
a drug that has been studied in Japan and is now approved for
both SCLC and non-small cell lung cancer (NSCLC). Am-
rubicin is being evaluated in the United States and Europe in
the treatment of patients with SCLC.
AMRUBICIN
Amrubicin (Figure 1) was discovered and developed by
Sumitomo Pharmaceuticals in Japan.12 It is a synthetic 9-ami-
noanthracycline with potent antitumor activity against vari-
ous human tumor xenografts.13
Amrubicin is metabolized to the active metabolite am-
rubicinol, which has five to 200 times higher growth inhibi-
tory activity against human tumor cell lines in vitro compared
with doxorubicin. The in vitro growth inhibitor activity of
amrubicinol was comparable with or higher than that of
doxorubicin. In human xenograft models, antitumor effects
on administration of amrubicin were highly correlated with
the intratumor concentration of amrubicinol. In this regard,
amrubicin is distinct from other anthracyclines for which
metabolites have equal or decreased cytotoxic activity rela-
tive to the parent compounds. In human xenograft models,
amrubicin exhibited antitumor effects comparable with or
superior to those of doxorubicin, when both were adminis-
tered at their maximum tolerated dose.
Anthracyclines have been reported to have diverse molec-
ular effects (e.g., DNA intercalation, inhibition of topoisomerase
II, and stabilization of topoisomerase II cleavable complexes).
Amrubicin demonstrates decreased DNA intercalation com-
pared with doxorubicin. The decreased DNA interaction appears
to influence the intracellular distribution because amrubicin and
amrubicinol showed only 20% distribution into the nucleus of
P388 cells compared with the 80% nuclear distribution observed
with doxorubicin. The cell growth inhibitory effects of amrubi-
cin and amrubicinol appear to be primarily related to inhibition
of topoisomerase II.14 Compared with doxorubicin, amrubicin,
and amrubicinol display stronger topoisomerase II–dependent
cleavage most probably due to the increased stability of the
complex formed by the drug, DNA, and the enzyme.
The primary metabolite (amrubicinol) in rats and dogs
is a product of reduction by cytoplasmic carbonyl reductase at
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the C-13 carbonyl group. Other enzymes participating in the
metabolism of amrubicin and amrubicinol were nicotinamide
adenine dinucleotide phosphate, reduced form (NADPH)–
P450 reductase and nicotinamide adenine dinucleotide [phos-
phate] (NAD[P]H)-quinone oxidoreductase. Twelve additional
metabolites were detected in vivo and in vitro. These included
four aglycone metabolites, two amrubicinol glucuronides,
deaminated amrubicin, and five highly polar unknowns. In
vitro cell growth inhibitory activity of the minor metabolites
was substantially lower than that of amrubicinol. Excretion of
amrubicin and its metabolites is primarily hepatobiliary. En-
terohepatic recycling was demonstrated in rats.
Single-dose studies were conducted in mice, rats, and
dogs, and repeated-dose evaluations were conducted for dos-
ing periods up to 6 months in rats and dogs. Additional
repeated-dose studies were conducted in rabbits and dogs to
evaluate the cardiotoxicity potential of amrubicin compared
with that of doxorubicin.
Based on acute intravenous dose toxicity studies, the
lethal dose to 50% of animals was estimated to be 42 mg/kg
in mice, 14 mg/kg in rats, and 4 mg/kg in dogs. The primary
target organs of amrubicin toxicity were similar across spe-
cies. Histopathologic lesions were found in tissues with
relatively rapid cellular turnover, i.e., hematopoietic and
lymphatic systems, the digestive tract, the reproductive sys-
tems, and hair follicles and were similar across species. In an
acute mouse study, a low incidence of kidney toxicity was
also observed.
Clinical manifestations of toxicity observed on acute
and repeated administration of amrubicin in rats and dogs
were dose related and reversible including fecal changes
(mucoid or bloody feces/diarrhea), body weight decreases,
decreased food consumption, decreased activity, and alope-
cia. Similar findings were observed at doses of doxorubicin
approximately one half those of amrubicin.
Results from the amrubicin toxicology program show
that hematologic parameters are the most important parame-
ters to monitor in clinical studies. In addition, studies in
rabbits and dogs determined that amrubicin did not induce
cardiomyopathy nor exacerbate doxorubicin-induced cardio-
myopathy.15,16 Amrubicin demonstrated reproductive and de-
velopmental toxicity in rabbits and rats. It also was shown to
be mutagenic.
Clinical development of amrubicin was initiated in
December 1986. It was approved for use in Japan for the
treatment of NSCLC and SCLC in April 2002.
The maximum tolerated dose of amrubicin was deter-
mined to be 130 mg/m2 in a single-dose schedule,17 25
mg/m2/day (125 mg/m2 in total) in daily doses for 5 days, and
50 mg/m2/day (150 mg/m2 in total) for 3 days. The dose-
limiting toxicity was myelosuppression (neutropenia 
thrombocytopenia and anemia). Leukopenia and neutropenia
developed in 80% of the patients who received amrubicin.
The incidence and severity were affected by previous treat-
ment, target lesion, and administration dose. Decreased he-
moglobin level (71%) and thrombocytopenia (35%) also
developed at relatively high frequency.
The plasma pharmacokinetics of amrubicin in cancer
patients are characterized by low total clearance (22% of total
TABLE 1. Drugs for Previously Untreated Patients with
Extensive-Stage Small Cell Lung Cancer
Agent
Patients
(assessable)
Response
Rate (%)
Median
Survival (mo)
Paclitaxel4 36 (32) 34 9.9
Paclitaxel5 43 (37) 41 (68%)a 6.6
Docetaxel6 47 (43) 23 9
Topotecan7 48 (48) 39 9
Irinotecan8 16 (15) 47 6.8
Irinotecan9 8 (8) 50 NR
Vinorelbine10 30 (27) 27 NR
Gemcitabine11 29 (26) 27 12
a Ten additional regressions of assessable disease for an overall major response rate
of 68%.
FIGURE 1. Structure of amrubicin.
Chemical name: (7S,9S)-9-acetyl-9-
amino-7-[(2-deoxy--D-erythro-pen-
topyranosyl)oxy]-7,8,9,10-tetrahy-
dro-6,11-dihydroxy-5,12-
naphthacenedione hydrochloride.
Molecular weight: 519.93.
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liver blood flow) and a moderate volume of distribution (1.4
times total body water). Amrubicin plasma concentrations
followed a biphasic pattern with peak concentrations ob-
served immediately after dosing followed by  and  half-
lives (t1/2)  SD of 0.06  0.01 and 2.0  0.3 hours,
respectively. Concentrations of amrubicin in red blood cells
(RBCs) were similar to those observed in plasma. Amrubicin
plasma and red blood cell pharmacokinetic parameters were
linear over a 10- to 130-mg/m2 dose range as evidenced by
dose proportional increases in the area under the curve (AUC)
and dose-independent t1/2. Amrubicin concentrations in
plasma and RBCs and t1/2 values after three and five
consecutive daily doses were similar to those observed
after the first dose, suggesting that amrubicin pharmaco-
kinetic parameters were not altered on repeated adminis-
tration (amrubicin hydrochloride investigator’s brochure
[IND 22,883], 2005).
Peak plasma concentrations of the active metabolite
amrubicinol were observed from immediately after dosing to
1 hour after dosing. Plasma concentrations of amrubicinol
were low compared with amrubicin plasma concentrations,
and the average plasma amrubicinol t1/2  SD was 15  8
hours. The plasma amrubicinol AUC was approximately
10-fold lower than the amrubicin plasma AUC. Concentra-
tions of amrubicinol were higher in RBCs as compared with
plasma. Amrubicinol AUCs ranged from 2.5-fold to 57.9-fold
higher in RBCs compared with plasma; however, the t1/2 of
amrubicinol in RBCs was 14  3 hours and thus was similar
to the plasma value. Because amrubicinol distributes into
RBCs to a greater extent than amrubicin, the concentrations
of amrubicinol and amrubicin in RBCs were similar. The
AUC of amrubicinol in RBCs was approximately twofold
lower than the amrubicin RBC AUC (amrubicin hydrochlo-
ride investigator’s brochure [IND 22,883], 2005).
Amrubicinol plasma and RBC AUCs increased in pro-
portion to amrubicin dose and t1/2 was independent of dose,
suggesting linear PK. Upon repeated daily amrubicin admin-
istration, amrubicinol accumulation was observed in plasma
and RBCs. On day 3, the amrubicinol plasma AUC was
1.2-fold to 6-fold higher than day 1 values; the RBC AUC
was 1.2-fold to 1.7-fold higher than day 1 values. After 5
consecutive daily doses, plasma and RBC amrubicinol AUCs
were 1.2-fold to 2.0-fold higher than day 1 values (amrubicin
hydrochloride investigator’s brochure [IND 22,883], 2005).
Urinary excretion of amrubicin and amrubicinol after
administration of amrubicin accounted for 2.7% to 19.6% of
the dose. The amount of excreted amrubicinol was approxi-
mately 10-fold greater than excreted amrubicin (amrubicin
hydrochloride investigator’s brochure [IND 22,883], 2005).
The intravenous administration of amrubicin at a dose
of 45 mg/m2/day for three consecutive days at 3-week inter-
vals is the approved schedule used in Japan.
AMRUBICIN AS FIRST-LINE THERAPY
In the first phase II study of amrubicin in previously
untreated patients with extensive-stage SCLC, an overall
response rate of 78.8% was reported18 ( Table 2). Thirty-five
patients were entered in the study of which 33 were eligible. TA
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The median age of the eligible patients was 66 years (range,
42–78), 29 were male and Eastern Cooperative Oncology
Group performance statuses (PSs) were PS 0–5, PS 1–26, PS
2–2. Amrubicin was administered by intravenous injection of
45 mg/m2/day for three consecutive days every 3 weeks. The
median number of courses of therapy was four (range, one to
six). Of the 33 eligible patients, five had a complete response
(15.2%) and 21 patients had a partial response (63.6%), for an
overall response rate of 78.8%. The median survival was 11.3
months (range, 2–21). The 1- and 2-year overall survival
rates were 46.9% and 23.1%, respectively. The major toxicity
was myelosuppression. Grade 3 and 4 leukopenia and neu-
tropenia was 39% and 39% and 12% and 39%, respectively.
Nonhematologic toxicity of grade 3 and higher was not
observed except for anorexia (9.1%) and alopecia (3%).
Cardiac toxicity was not observed.
AMRUBICIN IN MEDICALLY UNFIT OR HEAVILY
PRETREATED PATIENTS
Amrubicin monotherapy was also tested in patients
with SCLC who were unable to tolerate combination chemo-
therapy because of old age, poor PS, or other contraindica-
tions or patients who had previously undergone two or more
regimens of chemotherapy.19 Twenty-one patients were treated
with amrubicin given on days 1, 2, and 3 every 3 weeks.
Amrubicin was administered at 40 mg/m2 (or 35 mg/m2 for
six patients in consideration of their general health). Seven
patients were chemonaive. The overall response rate was
71% (five of seven patients) in chemonaive patients and 14%
(two of 14) in patients with previous chemotherapy. Median
survival time was 9.4 months (95% confidence interval:
7.7–14.1) and 6 months (95% confidence interval: 2.6–8.6),
respectively. Hematologic toxicity was common and rela-
tively severe, whereas nonhematologic toxicity was relatively
mild.19 Therefore, amrubicin monotherapy could be consid-
ered for patients with SCLC who are unfit for combination
chemotherapy.
AMRUBICIN PLUS CISPLATIN
In a phase I/II study, amrubicin and cisplatin in previ-
ously untreated patients with extensive-stage SCLC were
studied.20 Amrubicin (40–45 mg/m2/day) on days 1 to 3 and
cisplatin 60 mg/m2) on day 1 were administered intrave-
nously every 3 weeks to patients with a good PS. Four and
three patients received the amrubicin dose of 40 (level 1) and
45 mg/m2/day (level 2), respectively. The maximum tolerated
dose was determined to be the 45 mg/m2/day of amrubicin
plus cisplatin 60 mg/m2, whereas the recommended phase II
dose was the lower dose of amrubicin plus cisplatin. No
dose-limiting toxicities were observed during the first course
of level 1, whereas at level 2, grade 4 febrile neutropenia
occurred in two patients. An additional 37 patients were
entered in the study. A total of 41 patients were a treated at
the recommended phase II dose. The response rate was 87.8%
(10% complete response). The median survival time and
1-year survival rate were 13.6 months and 56.1%, respec-
tively. Grade 3/4 neutropenia and leukopenia occurred on
95.1% and 65.9% of patients, respectively. Grade 3 throm-
bocytopenia occurred in 24% of patients, and grade 3/4
hyponatremia was present in 22% of patients.
AMRUBICIN PLUS TOPOTECAN
A phase I study of amrubicin and topotecan in patients
who were either chemotherapy naive or relapsed with exten-
sive-stage SCLC was conducted.21 Topotecan was adminis-
tered on days 1 to 5, and amrubicin was administered on days
3 to 5. Cycles were to be repeated every 4 weeks. Nine
patients (four chemonaive, five relapsed [three patients with
sensitive disease, two patients with refractory disease]) were
treated. The dose-limiting toxicity was neutropenia, febrile
neutropenia, and thrombocytopenia. The maximum tolerated
dose for topotecan was 0.75 mg/m2 and 40 mg/m2 for
amrubicin. Six patients (67%) had a partial response to the
therapy (four of five [80%] relapsed patients and two of four
[50%] chemonaive patients). The median time to progression
was 4 months.
AMRUBICIN AS SECOND-LINE THERAPY
In a phase II study conducted in previously treated
patients with SCLC, amrubicin 40 mg/m2/day intravenously
was administered for three consecutive days every 3 weeks.22
Twenty-six patients (nine sensitive-disease, 17 refractory-
disease patients), 22 men, four women; median age, 62.5
years (range, 43–78) received a median number of three
cycles of therapy. The response rate was 46.2% (55.6%
sensitive disease, 41.2% refractory disease). The median
survival time was 9.4 months (11.0 months for sensitive
disease, 5.7 months for refractory disease). Grade 4 leukope-
nia and neutropenia occurred in 42.3% and 73.1% of patients,
respectively. Grade 3 or 4 thrombocytopenia occurred in 50%
of patients.
The Japanese Thoracic Oncology Research Group con-
ducted a phase II study of amrubicin for the treatment of
previously treated SCLC.23 It is the largest study evaluating
this drug in this patient population. Patients were eligible for
the study if they had measurable disease and an Eastern
Cooperative Oncology Group PS of 0–2, were previously
treated with at least one platinum-based chemotherapy regi-
men, and either had refractory disease (failed first-line treat-
ment 60 days from discontinuing treatment) or sensitive
disease (progressed 60 days after discontinuing treatment).
Amrubicin 40 mg/m2/day was administered as a
5-minute intravenous injection for three consecutive days
every 3 weeks.23 Sixty patients (16 with refractory disease
and 44 with sensitive disease) were entered in the study. The
median number of cycles given was four (range, one to eight).
The overall response rates were 52% (1.9% complete re-
sponse) in the sensitive-disease group and 50% (2% complete
response) in the refractory-disease group of patients. The
overall and 1-year survival rate in the sensitive-disease group
were 11.6 months and 45.5%, respectively, whereas in the
refractory-disease group, they were 10.3 months and 40.3%,
respectively. The major toxicity was hematologic. Grade 3/4
toxicities occurred as follows: neutropenia, 83.3%; leukope-
nia, 70.0%; anemia, 33.3%; thrombocytopenia, 20%; an-
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orexia, 15%; and asthenia, 15%. Nonhematologic toxicity
was relatively mild. No cardiac toxicity was observed.
DISCUSSION
The only drug approved for second-line treatment of
SCLC in the United States is topotecan (Hycamtin). The U.S.
Food and Drug Administration approved it on November 30,
1998. In part, their decision was based on the results of a
phase III multicenter study of SCLC patients who relapsed
60 days after completion of first-line chemotherapy and
then were randomized to receive either topotecan or cyclo-
phosphamide, doxorubicin, and vincristine (CAV).24 The
patient population was considered as having SCLC sensitive
disease. The response rate to topotecan-treated patients was
24.3% compared with 18.3% for the patients receiving CAV
(p  0.285). The median survival was 25.0 weeks for the
topotecan-treated patients and 24.7 weeks for the CAV-
treated patients (p  0.795). There was greater symptom
improvement (shortness of breath, anorexia, hoarseness, and
fatigue) and less toxicity associated with topotecan treatment
compared with CAV treatment.
In an earlier phase II study,25 SCLC patients were
stratified as having refractory or sensitive disease and given
topotecan as second-line therapy. In the study, patients with
refractory disease were defined as patients who relapsed 90
days after first-line chemotherapy for the treatment of SCLC.
Patients with sensitive disease was defined as SCLC patients
who relapsed 90 days after completion of initial chemo-
therapy. In sensitive-disease SCLC patients, the response rate
was 37.8%, whereas in refractory-disease patients, it was
6.4%. The median survival for all patients was 5.4 months,
and for sensitive-disease patients, it was 6.9 months.
Although studies have shown that topotecan is effective
as a second-line treatment of SCLC patients, especially those
who have chemosensitive disease, it has not had a significant
impact on the survival of such patients. New therapies are
needed to inhibit distant metastasis and thereby improve
survival rates of SCLC patients.
Is amrubicin one of these new therapies? In Japan, as a
single agent and in combination with other agents, it appears
to be effective in treating extensive-stage SCLC patients
especially as second-line therapy. However, thus far, the
studies reported of its effectiveness are small and there has
been no phase III study to evaluate its effectiveness compared
with standard treatments.
In addition, can its effectiveness in treating Japanese
patients with extensive-stage SCLC be reproduced in West-
ern patients with the disease? If not, will this be another
situation of possible geographic and/or ethnic variation in the
effectiveness of the same treatment given to patients with
geographic and ethnic differences.
The most striking example of the above has been seen
in both the activity and toxicity of the tyrosine kinase inhib-
itor gefitinib in the treatment of NSCLC patients in Japan and
the United States.26–28 Japanese patients had a higher re-
sponse rate (28%) and longer median survival (12 months)
compared with U.S. patients who had a response rate of 10%
and median survival of 6 to 7 months receiving gefitinib. In
addition, 2% of Japanese patients developed interstitial lung
disease associated with gefitinib administration, whereas no
U.S. patients developed the toxicity.
Does geographic and/or ethnic variation apply to the
effectiveness of irinotecan plus cisplatin compared with eto-
poside plus cisplatin for extensive-stage SCLC? In a Japanese
phase III study, the median survival 12.8 months for SCLC
patients treated with irinotecan/cisplatin compared with 9.4
months (p  0.002) for the patients treated with etoposide/
cisplatin. The survival rate at 2 years was 19.5% for the
patients treated with irinotecan/cisplatin and 5.2% for the
patients treated with etoposide/cisplatin.29
In a U.S. phase III study comparing irinotecan/cisplatin
with etoposide/cisplatin in SCLC patients, there was no
improvement in survival in the patients receiving irinotecan/
cisplatin.30 The median survival was 9.3 months versus 10.2
months (p  0.74). In this study, the patients appeared to
have more advanced disease compared with the patients in
the Japanese study. In addition, a different dose and schedule
of irinotecan/cisplatin was used in the U.S. study.
There is an ongoing Southwest Oncology Group study
comparing irinotecan/cisplatin with etoposide/cisplatin using
the same dose and schedule as in the Japanese study to treat
patients with extensive-stage SCLC.
Why are there these differences between the Japanese
patients and U.S. patients? Is it geographic variations in
treatment? In the former study, this may be operative because
of health care economics, the influence of regulatory agen-
cies, and physician biases.31 In addition, in both the former
and latter studies, another explanation could be biologic
differences between Japanese and U.S. patients in regard to
pharmacogenomic aspects of drug metabolism or differences
in tumor susceptibility affecting efficacy and toxicity.31
What genetic variations might explain the effectiveness
of amrubicin in Japanese patients with SCLC? It is known
that polymorphisms of NQ01 subunits affect doxorubicin
efflux transporters, thereby increasing the risk of anthracy-
cline-induced cardiotoxicity.32 In addition, NQ01 detoxifies
quinones derived from the oxidation of phenolic metabolites
of benzene. Individuals homozygous for the 609C-T poly-
morphisms (T/T genotype) have an increased risk of benzene
poisoning. In cells with the T/T genotype, NQ01 was not
detected. The prevalence of the T/T genotype was highest in
the Asian populations.33 NAD(P)H-quinone oxidoreductase
is an enzyme that participates in the metabolism of amrubicin
and amrubinol. Will polymorphisms of NAD(P)H oxidase
possibly explain the effectiveness of amrubicin in treating
Japanese patients?
Because amrubicin appears to be the most effective
single agent to treat SCLC, at least in Japan, and has not yet
been tested outside Japan, it is necessary to confirm its
effectiveness in U.S. patients with SCLC. Recently, a ran-
domized phase II tried comparing amrubicin with topotecan
as second-line treatment in patients with extensive-stage
SCLC sensitive to first-line chemotherapy has been initiated
sponsored by Cabrellis Pharmaceuticals Corporation, San
Diego, CA. A phase II single-arm study will evaluate the
effectiveness of the drug in patients refractory to first-line
Ettinger Journal of Thoracic Oncology • Volume 2, Number 2, February 2007
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chemotherapy and a randomized phase II study of amrubicin
versus cisplatin and etoposide will evaluate the activity of
amrubicin in European patients in first-line SCLC.
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